Destroying Cancer From The Inside Out

Introducing a Promising New Treatment

A Combination Cancer Therapy

Real-Time Cellular-Guided Radiation Therapy
Boron Neutron Capture Therapy (BNCT) is a non-invasive, combination radiation therapy, which selectively destroys cancer cells while sparing healthy tissue. BNCT has been used to treat cancers that are inoperable, invasive, radioresistant or spread outside the primary tumor site in as little as a single treatment session.

Benefits of BNCT

Global research shows BNCT provides the following benefits

Biophysical Precision

Effective in treating recurrent, multiple, and untreated cancers

Targets cancer at cellular level

Selectively destroys only cancer cells

Eliminates the need for respiratory gating and internal markers

Efficient Treatment

One to two treatment sessions

Treats primary and undetected local microscopic cancer cells in parallel

Potential for more patient throughput than other radiation therapies

Better Patient Experience

Does not require high-level patient positioning – improving patient comfort and reducing staff workload

Potential to greatly reduce side effects and improve patient quality of life

* All BNCT treatments to date have been conducted under clinical investigations.
** Moss, R. L. Critical review, with an optimistic outlook, on Boron Neutron Capture Therapy (BNCT). Applied Radiation and Isotopes 88 (2014), 2–11.Sauvolainen, S., et al. Boron neutron capture therapy (BNCT) in Finland: Technological and physical prospects after 20 years of experiences. Physica Medica (2013) 29, 233-248
** Coderre and Morris (1999) The Radiation Biology of Boron Neutron Capture Therapy. Radiation Research: January 1999, Vol 151, No. 1, pp. 1-18.

A Novel Accelerator-Based Neutron Source

TAE Life Sciences is developing a novel cellular targeted radiation (CtRT) treatment based on boron neutron capture therapy (BNCT). Our compact tandem accelerator based neutron source in combination with targeted boron-10 drugs will allows us to make BNCT available in a hospital to provide patients with potential better outcomes.

* The TAE Life Sciences machine is in development and only available for investigational use and not available commercially.

Clinical Partners

We are looking to partner with hospitals and research institutions to initiate clinical trials to validate the next generation of BNCT.

Investor Relations

TAE Life Sciences is interested in speaking with potential investors whose charter aligns with our mission.